![]() |
市场调查报告书
商品编码
1880532
实验室耗材市场预测至2032年:按产品类型、材料类型、分销管道、应用、最终用户和地区分類的全球分析Lab Supplies Market Forecasts to 2032 - Global Analysis By Product Type (Equipment, Consumables, and Other Product Types), Material Type, Distribution Channel, Application, End User and By Geography |
||||||
根据 Stratistics MRC 预测,全球实验室耗材市场规模预计在 2025 年达到 500.2 亿美元,并在 2032 年达到 944.2 亿美元,预测期内复合年增长率 (CAGR) 为 9.5%。实验室耗材涵盖科学、医疗和工业实验室活动所需的基本材料、耗材和设备,包括玻璃器皿、塑胶耗材、化学品、移液器、防护设备以及样品製备和检测工具。这些耗材对于确保结果准确、维持流程一致性以及创造安全的工作环境至关重要。它们支持学术界、临床界和商界开展的各种实验室活动,包括研究、诊断检测、实验和品质保证等。
根据 Peterson-KFF 医疗系统追踪器发表的报导,2020 年美国医疗费用支出成长了 9.7%,达到 4.1 兆美元,这一增幅远高于 2019 年的 4.3%。
增加研发投入
科研活动的激增推动了对高品质实验室耗材、分析仪器和先进样品处理工具的需求。自动化、人工智慧驱动的工作流程系统和高通量筛检平台等技术进步进一步推动了对现代化实验室耗材的需求。学术机构和合约研究组织(CRO)正在扩大其研究范围,从而增加了采购量。基因组学、药物研发和分子诊断领域的投资不断增长,促使实验室采用更精确、可重复且数位化整合的仪器。随着全球科学研究生态系统的日益成熟,实验室耗材製造商正在加速创新,以支持新的科学应用。
熟练人员短缺
许多机构难以操作先进设备,例如自动化分析仪、定序平台和基于人工智慧的实验室资讯系统。人才短缺导致各机构和研究中心更加依赖大规模的培训项目,从而增加了营运成本。尤其是小规模的实验室,由于缺乏具备必要专业知识的人员,在整合升级设备方面面临许多挑战。此外,监管合规和品质保证方面的复杂性也给人员不足的实验室带来了更大的负担。
自动化和人工智慧/物联网集成
自动化液体处理系统、智慧离心机和云端基础的库存管理平台正在提高精度并减少人为错误。物联网监控工具正在帮助改善资产追踪、耗材使用预测和品管。人工智慧演算法正在支援预测性维护和即时工作流程优化。这些技术使实验室能够扩大产能、更快地提供检测结果并提高结果的可重复性。随着自动化技术的普及,供应商正在为研发、临床诊断和工业实验室开发客製化、模组化且易于使用的解决方案。
激烈的价格竞争
微量吸管尖、试管和试剂等耗材的商品化导致价格竞争加剧,利润率不断下降。低成本供应商(尤其是来自新兴市场的供应商)的崛起正在重塑采购格局。为了保持竞争力,主要企业正投资于精益生产、自动化生产和数位化分销平台。对价格敏感的客户倾向于大量采购、可重复使用产品和高性价比产品,这迫使企业实现产品线多元化。
全球供应链的严重中断迫使实验室紧急重新思考其筹资策略并加强库存韧性。此次危机加速了自动化样本处理、远距离诊断和云端基础的实验室管理解决方案的普及。紧急监管途径加快了诊断材料和侦测设备的核准。疫情过后,实验室继续优先考虑准备工作、自动化和分散式检查模式。这种转变永久增加了对高品质、扩充性且数位化整合的实验室耗材的需求。
预计在预测期内,设备细分市场将占据最大的市场份额。
由于设备在支援广泛的研究、诊断和分析活动中发挥至关重要的作用,预计在预测期内,设备领域将占据最大的市场份额。光强度、培养箱、离心机和生物安全柜等先进设备的日益普及,巩固了该领域的主导地位。触控萤幕介面、物联网监控和节能设计等持续的技术创新,正在提升设备的运作效能。生物製药研发和分子生物学研究的拓展,推动了对精密仪器的需求。实验室也在对其旧有系统进行升级改造,以整合自动化和智慧连接功能。
预计在预测期内,临床和诊断检查室领域将呈现最高的复合年增长率。
预计在预测期内,临床和诊断检查室领域将实现最高成长率,这主要得益于检测量的成长、感染疾病监测范围的扩大以及预防保健意识的提高。分子诊断、免疫检测和照护现场平台技术的进步正在推动高性能检测耗材的普及。这些检查室越来越依赖自动化分析仪、快速检测套组和数据驱动的工作流程系统来提高效率。数位化实验室资讯管理系统(LIMS)平台和基于人工智慧的诊断工具能够加快检体追踪和临床决策速度。分散式检查中心的扩张和私人诊断连锁机构的发展正在推动耗材和设备的采购。
亚太地区预计将在预测期内占据最大的市场份额,这主要得益于医疗基础设施、生物医学研究和诊断能力的快速发展。中国、印度、日本和韩国等国家正大力投资检查室现代化以及设备和耗材的本土化生产。政府对生物技术、精准医疗和药物研发的投入也推动了对先进检测用品的需求。此外,该地区自动化、人工智慧驱动的分析和基于机器人的研究平台也得到了更广泛的应用。全球製造商与区域企业之间的合作正在促进技术转移并降低成本。
在预测期内,北美预计将展现出最高的复合年增长率,这主要得益于强劲的技术创新和对科学研究的大量投入。该地区在基因组学、蛋白质组学、细胞疗法和人工智慧驱动的实验室操作等领域处于领先地位。实验室正在迅速采用数位化工作流程系统、智慧仪器和先进的自动化技术来提高生产力。完善的法规结构和资金筹措计划正在促进新型实验室技术的快速商业化。顶尖大学、生物製药公司和临床研究机构正在推动高品质实验室耗材的持续高需求。
According to Stratistics MRC, the Global Lab Supplies Market is accounted for $50.02 billion in 2025 and is expected to reach $94.42 billion by 2032 growing at a CAGR of 9.5% during the forecast period. Laboratory supplies encompass the fundamental materials, consumables, and instruments required for conducting scientific, medical, and industrial lab activities. They include items such as glassware, plastic consumables, chemicals, pipettes, protective equipment, and tools used for sample preparation and testing. These supplies are vital for ensuring accurate results, consistent processes, and safe working conditions. They support a wide range of laboratory functions, including research, diagnostic testing, experimentation, and quality-assurance tasks in academic, clinical, and commercial settings.
According to an article published by the PETERSON-KFF Health System Tracker, healthcare spending in the U.S. increased by 9.7% and reached USD 4.1 trillion in 2020, significantly faster than the 4.3% increase in 2019.
Increasing R&D investment
The surge in research activity is intensifying the need for high-quality lab consumables, analytical instruments, and advanced sample-processing tools. Technological advancements such as automation, AI-enabled workflow systems, and high-throughput screening platforms are further boosting demand for modern lab supplies. Academic institutes and CROs are expanding their research scope, encouraging higher procurement volumes. Growing investment in genomics, drug discovery, and molecular diagnostics is pushing laboratories to adopt more precise, reproducible, and digitally integrated equipment. As global research ecosystems mature, lab supply manufacturers are accelerating innovation to support emerging scientific applications.
Shortage of skilled personnel
Many facilities struggle with operating sophisticated instruments such as automated analyzers, sequencing platforms, and AI-based laboratory information systems. This talent gap increases dependency on extensive training programs, raising operational costs for institutions and research centers. Small laboratories, in particular, face challenges integrating upgraded equipment due to limited staffing expertise. The complexity of regulatory compliance and quality assurance adds further burden to understaffed labs.
Integration of automation and AI/IoT
Automated liquid handling systems, smart centrifuges, and cloud-based inventory platforms are enabling greater accuracy and reducing manual errors. IoT-enabled monitoring tools are improving asset tracking, consumable usage prediction, and quality control. AI algorithms are now supporting predictive maintenance and real-time workflow optimization. These technologies are allowing laboratories to scale capacity, accelerate testing turnaround times, and enhance reproducibility. As automation becomes more accessible, suppliers are developing modular, user-friendly solutions tailored for research, clinical diagnostics, and industrial laboratories.
Intense price competition
The commoditization of consumables such as pipette tips, tubes, and reagents has led to competitive pricing strategies and shrinking margins. Increased presence of low-cost suppliers, especially from emerging markets, is reshaping procurement dynamics. To stay competitive, key players are investing in lean manufacturing, automation-driven production, and digital distribution platforms. Price-sensitive customers are opting for bulk procurement, reusable items, and value-tier products, pushing companies to diversify their offerings.
Global supply chains faced severe disruptions, prompting laboratories to reassess sourcing strategies and strengthen inventory resilience. The crisis also stimulated rapid adoption of automated sample handling, remote diagnostics, and cloud-based lab management solutions. Emergency regulatory pathways facilitated quicker approval of diagnostic materials and testing equipment. Post-pandemic, laboratories continue to prioritize preparedness, automation, and decentralized testing models. This shift has permanently amplified demand for high-quality, scalable, and digitally integrated lab supplies.
The equipment segment is expected to be the largest during the forecast period
The equipment segment is expected to account for the largest market share during the forecast period, due to its essential role in supporting a wide range of research, diagnostic, and analytical activities. High adoption of advanced instruments such as spectrophotometers, incubators, centrifuges, and biosafety cabinets is strengthening this segment's leadership. Continuous technological advancements, including touchscreen interfaces, IoT-enabled monitoring, and energy-efficient designs, are improving operational performance. The expansion of biopharma R&D and molecular biology studies is driving demand for precision equipment. Laboratories are also upgrading legacy systems to integrate automation and smart connectivity.
The clinical & diagnostic laboratories segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the clinical & diagnostic laboratories segment is predicted to witness the highest growth rate, due to rising testing volumes, expanding infectious disease surveillance, and increased preventive healthcare awareness. Advancements in molecular diagnostics, immunoassays, and point-of-care platforms are boosting the adoption of high-performance lab supplies. These labs increasingly rely on automated analyzers, rapid test kits, and data-driven workflow systems to improve efficiency. Digital LIMS platforms and AI-based diagnostic tools are enabling faster sample tracking and quicker clinical decisions. The expansion of decentralized testing centers and private diagnostic chains is fueling procurement of consumables and equipment.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rapid expansion of healthcare infrastructure, biomedical research, and diagnostic capacity. Countries such as China, India, Japan, and South Korea are investing heavily in laboratory modernization and local production of equipment and consumables. Government funding for biotechnology, precision medicine, and pharmaceutical R&D is accelerating demand for advanced lab supplies. The region is also experiencing rising adoption of automation, AI-driven analytics, and robotics-based research platforms. Collaborative partnerships between global manufacturers and regional players are enhancing technology transfer and affordability.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong technological innovation and substantial investment in scientific research. The region leads advancements in genomics, proteomics, cell therapy, and AI-driven laboratory operations. Laboratories are rapidly integrating digital workflow systems, smart instruments, and advanced automation to enhance productivity. Supportive regulatory frameworks and funding programs are encouraging faster commercialization of new lab technologies. Major universities, biopharma companies, and clinical research organizations consistently drive high consumption of premium lab supplies.
Key players in the market
Some of the key players in Lab Supplies Market include Thermo Fisher Scientific, QIAGEN N.V., Danaher Corporation, Shimadzu Corporation, Merck KGaA, Mettler-Toledo, Agilent Technologies, Waters Corporation, Sartorius AG, Bruker Corporation, Avantor Inc., PerkinElmer, Corning Incorporated, Bio-Rad Laboratories, and Eppendorf.
In October 2025, Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holdings and Cinven, for $8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.
In October 2025, Merck has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery. The agreement unites Merck's strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.